Riikonen P, Saarinen U M, Lähteenoja K M, Jalanko H
Children's Hospital, University of Helsinki, Finland.
Scand J Infect Dis. 1993;25(3):357-64. doi: 10.3109/00365549309008511.
This prospective study comprises 97 episodes of fever and neutropenia in children with cancer and central venous access. In 76% of episodes, patients had a Broviac-Hickman-like catheter, and in 24% a totally implanted venous access chamber system. The need for catheter removal during a febrile infection was 0.32/1000 catheter days, and the documented sepsis rate was 0.59/1000 catheter days. Our data indicate that 94% of episodes of fever and neutropenia in total, 78% of documented septicemias, and 97% of fevers of unknown origin were curable with broad-coverage antimicrobial therapy without removing the central venous line. Totally implanted chambers had a lower infection rate than catheters of Broviac-Hickman type.
这项前瞻性研究纳入了97例患有癌症且有中心静脉通路的儿童发热伴中性粒细胞减少症病例。在76%的病例中，患者使用的是类似Broviac - Hickman的导管，24%的病例使用的是完全植入式静脉通路腔系统。发热感染期间导管拔除率为0.32/1000导管日，记录的败血症发生率为0.59/1000导管日。我们的数据表明，总体上94%的发热伴中性粒细胞减少症病例、78%记录的败血症病例以及97%不明原因发热病例，在不拔除中心静脉导管的情况下，通过广泛覆盖的抗菌治疗均可治愈。完全植入式腔系统的感染率低于Broviac - Hickman型导管。
